WO2011045760A2 - Micronized olmesartan medoxomil compositions - Google Patents

Micronized olmesartan medoxomil compositions Download PDF

Info

Publication number
WO2011045760A2
WO2011045760A2 PCT/IB2010/054641 IB2010054641W WO2011045760A2 WO 2011045760 A2 WO2011045760 A2 WO 2011045760A2 IB 2010054641 W IB2010054641 W IB 2010054641W WO 2011045760 A2 WO2011045760 A2 WO 2011045760A2
Authority
WO
WIPO (PCT)
Prior art keywords
μπι
pharmaceutical composition
particles
composition
olmesartan medoxomil
Prior art date
Application number
PCT/IB2010/054641
Other languages
French (fr)
Other versions
WO2011045760A3 (en
Inventor
Arun Gupta
Madhusudan Vattikonda
Anupam Trehan
Vinod Kumar Arora
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2011045760A2 publication Critical patent/WO2011045760A2/en
Publication of WO2011045760A3 publication Critical patent/WO2011045760A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to pharmaceutical compositions comprising micronized particles of olmesartan medoxomil and processes thereof.
  • Olmesartan medoxomil chemically described as (5-methyl-2-oxo-l,3-dioxolen-4- yl)methyl-4-(l -hydroxy- 1 -methylethyl)-2-propyl- 1 - ⁇ 4- [2-(tetrazol-5-yl)phenyl] phenyl ⁇ methylimidazole-5-carboxylate, is widely used for the treatment of hypertension and related diseases and conditions due to its ability to inhibit the angiotensin-converting enzyme.
  • Olmesartan medoxomil is a prodrug, which is hydrolyzed to olmesartan during absorption from the gastrointestinal tract.
  • the pharmaceutical formulation currently approved for the administration of olmesartan medoxomil is a film-coated tablet, commercially available under the brand name Benicar ® . These tablets are being marketed by Daiichi Sankyo and are covered by U.S. Patent No. 5,616,599. It discloses olmesartan medoxomil and other related imidazoles. It also describes a process for the preparation of imidazole derivatives useful for the synthesis of olmesartan.
  • Olmesartan medoxomil is practically insoluble in water. This leads to a low rate of dissolution of olmesartan medoxomil in aqueous media (including gastrointestinal fluids), which results in inadequate bioavailability after oral ingestion.
  • WO 2007/047838 relates to a process of preparing olmesartan medoxomil having decreased impurities and a particle size distribution such that the do.9 is less than 250 ⁇ .
  • WO 2008/117707 relates to ground crystals of olmesartan medoxomil having particle size distribution such that the d 0 .9 is less than 75 ⁇ , preferably less than 66 ⁇ and most preferably less than 57 ⁇ .
  • the present inventors have found that further reduction of the particle size of olmesartan medoxomil (i.e., less than 50 ⁇ ), even without addition of a surfactant leads to remarkably improved solubility characteristics and as a result, a pharmaceutical composition having an improved dissolution profile is obtained.
  • the present invention provides for a pharmaceutical composition that includes micronized particles of olmesartan medoxomil having a d 0 .9 less than 50 ⁇ and one or more pharmaceutically acceptable excipients.
  • Embodiments of this aspect may include one or more of the following features.
  • the micronized particles of olmesartan medoxomil have a d 0 .9 between 2 ⁇ to 25 ⁇ .
  • the micronized particles of olmesartan medoxomil may have a d 0 .9 between 4 ⁇ to 10 ⁇ .
  • the micronized particles of olmesartan medoxomil are present in an amount of about 2% to about 80% by weight of the composition.
  • the pharmaceutical composition may further include one or more pharmaceutically acceptable excipients selected from a group comprising diluents, binders, disintegrants, lubricants, glidants, surfactants, coloring agents or flavoring agents.
  • the pharmaceutical composition is in the form of a tablet, dispersible tablet, capsule, granule, pellet, bead, powder, suspension, elixir or syrup.
  • the composition is prepared by directly encapsulating or directly compressing olmesartan with one or more excipients.
  • the composition may be prepared by wet granulating olmesartan with one or more excipients prior to encapsulation or compression.
  • the composition may also be prepared by dry granulating olmesartan with one or more excipients prior to encapsulation or compression.
  • the pharmaceutical composition is used for the treatment or prophylaxis of hypertension or of a cardiovascular disease by administering to a person in need thereof and may be administered in combination with an additional antihypertensive agent.
  • Suitable additional antihypertensive agents include one or more of thiazide diuretics, ⁇ -blockers, calcium channel blockers, rennin inhibitors or ACE inhibitors.
  • the composition may include micronized olmesartan medoxomil particles having a d 0 .9 less than 50 ⁇ and hydrochlorothiazide.
  • the present invention provides for a pharmaceutical composition that includes micronized olmesartan medoxomil particles and amlodipine, wherein the micronized olmesartan particles have a do.9 less than 50 ⁇ .
  • the present invention provides for olmesartan medoxomil particles having a d 0 .9 less than 50 ⁇ .
  • Embodiments of this aspect may include one or more of the following features.
  • the olmesartan medoxomil particles may have a do.9 between 2 ⁇ to 25 ⁇ or a do.9 between 4 ⁇ to 10 ⁇ .
  • the present invention provides a novel pharmaceutical composition comprising micronized olmesartan medoxomil and processes thereof.
  • olmesartan medoxomil includes crystalline or amorphous olmesartan medoxomil.
  • olmesartan medoxomil may be utilized in an amount ranging from 2% to 80% (w/w) based on the total weight of the pharmaceutical composition.
  • micronized olmesartan medoxomil means particles of olmesartan medoxomil having d 0 .9 less than 50 ⁇ , particularly between 1 ⁇ to 50 ⁇ , more particularly between 2 ⁇ to 25 ⁇ . Most particularly, it relates to olmesartan medoxomil particles having do.9 between 4 ⁇ to 10 ⁇ .
  • do.9 with reference to the size of micronized olmesartan medoxomil particles, indicate that about 90% of particles measured have a size less than the defined d 0 .9 value, and that about 10% of particles measured have a size greater than the defined d 0 .9 value.
  • terapéuticaally effective amount means a dosage that is sufficient to provide the specific pharmacological response for which the olmesartan medoxomil is being administered.
  • the “therapeutically effective amount” will vary depending on the severity of the disease, age, weight, physical condition and the responsiveness of the subject.
  • the particle size distribution of olmesartan medoxomil particles of the present invention may be determined using an optical microscopic method, sedimentation techniques, for example, pipette analysis using an Andreas sen pipette, sedimentation scales, photo sedimentometers or sedimentation in a centrifugal force field, pulse methods, for example, using a Coulter counter, or sorting by means of gravitational or centrifugal force, sieve analysis, laser diffraction or ultrasound attenuation spectroscopy.
  • the particle size distribution of olmesartan medoxomil particles of the present invention is particularly determined through laser diffraction using a Malvern® Mastersizer laser diffraction instrument.
  • the pharmaceutical composition that includes micronized olmesartan medoxomil may further comprise one or more pharmaceutically acceptable excipients selected from a group comprising diluents, binders, disintegrants, lubricants, coloring agents, flavoring agents or any other excipients known in the art.
  • Suitable examples of diluents include corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch, pregelatinized starch or mixtures thereof.
  • binders include polyvinylpyrrolidone, starch mucilage, pregelatinized starch, sodium alginate, alginic acid, acacia mucilage, tragacanth, hydroxypropylmethyl cellulose, carboxymethylcellulose sodium, carboxymethylcellulose calcium, microcrystalline cellulose, ethyl cellulose, polyethylene glycol, hydroxyethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polymethacrylates, carboxyvinyl polymers, carbopols, and combinations thereof.
  • Suitable examples of disintegrants include cross-linked polyvinylpyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose (crosscarmellose sodium), calcium carboxymethyl cellulose, alginic acid and alginates, pregelatinised starch, starch and starch derivatives, low-substituted hydroxypropyl cellulose and combinations thereof.
  • lubricants and glidants include colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, white beeswax or mixtures thereof.
  • Coloring agents and flavoring agents may be selected from any FDA approved colors and flavors for oral use.
  • compositions of the present invention may optionally contain surfactants.
  • Surfactants/wetting agents include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in pharmaceutical compositions. These include polyethoxylated fatty acid esters, polyethylene glycol fatty acid esters, alcohol-oil transesterification products, polyglycerized fatty acids, polyethylene glycol sorbitan fatty acid esters, sugar esters, polyoxyethylene-polyoxypropylene block copolymers, ionic surfactants, derivatives of fat soluble vitamins, and mixtures thereof.
  • Suitable examples include sodium lauryl sulphate, sodium dodecyl sulphate, polyoxyethylene castor oil derivatives, for example, tweens, polyoxyethylene-polyoxypropylene block copolymers, for example, poloxamer, or mixtures thereof.
  • the present invention further provides pharmaceutical composition that include micronized olmesartan medoxomil, wherein the composition may be in the form of tablets, dispersible tablets, capsules, granules, beads, pellets, powder, suspension, emulsion, syrups or elixirs.
  • the compositions of the present invention are formulated into tablets, capsules or dispersible tablets. Further, the tablets may be film-coated.
  • the tablets may be coated using a sugar-based agent, an agent for water-soluble film-coating base, enteric film-coating agent or a modified release film-coating agent.
  • the coating agent may also contain a plasticizer.
  • compositions of the present invention may be prepared by using the conventional techniques, for example, either by direct compression, or first slugging some of the ingredients, milling the slugs, blending with the remaining ingredients and then compressing as appropriate. These compositions may also be prepared using wet granulation techniques.
  • composition according to the present invention comprising micronized olmesartan medoxomil may be administered for the treatment or prophylaxis of hypertension or of a cardiocascular disease.
  • compositions, described herein can also be administered in combination with other antihypertensive agents selected from thiazide diuretics, ⁇ - blockers, calcium channel blockers, rennin inhibitors or ACE inhibitors.
  • Tablets containing olmesartan medoxomil having a do.9 of 116 ⁇ , 67 ⁇ , 22 ⁇ and 6 ⁇ respectively.
  • Olmesartan medoxomil and microcrystalline cellulose were sieved and blended together.
  • Lactose monohydrate and L-hydroxypropylcellulose were sieved and mixed with the blend of step (i).
  • step (iv) Blend of step (ii) was granulated using the binder solution of step (iii).
  • step (v) Granules of step (iv) were dried in a fluidized bed dryer.
  • step (v) Dried granules of step (v) were sieved.
  • step (viii) Finally the blend of step (vii) was compressed into tablets.
  • the tablets of olmesartan medoxomil prepared as per the compositions of Examples 1, 2, 3 and 4 were subjected to dissolution studies in 1000 ml of phosphate buffer (pH 6.8) at 37°C using USP apparatus II with paddle speed at 50 rpm.
  • Table 1 provides comparative dissolution profile.
  • Comparative dissolution profile of the Examples 1, 2, 3 and 4 indicate that as I particle size of olmesartan medoxomil decreases the dissolution percentage increases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising micronized particles of olmesartan medoxomil and processes thereof.

Description

MICRONIZED OLMESARTAN MEDOXOMIL COMPOSITIONS
Field of the Invention
The present invention relates to pharmaceutical compositions comprising micronized particles of olmesartan medoxomil and processes thereof.
Background of the Invention
Olmesartan medoxomil, chemically described as (5-methyl-2-oxo-l,3-dioxolen-4- yl)methyl-4-(l -hydroxy- 1 -methylethyl)-2-propyl- 1 - { 4- [2-(tetrazol-5-yl)phenyl] phenyl}methylimidazole-5-carboxylate, is widely used for the treatment of hypertension and related diseases and conditions due to its ability to inhibit the angiotensin-converting enzyme. Olmesartan medoxomil is a prodrug, which is hydrolyzed to olmesartan during absorption from the gastrointestinal tract.
The pharmaceutical formulation currently approved for the administration of olmesartan medoxomil is a film-coated tablet, commercially available under the brand name Benicar®. These tablets are being marketed by Daiichi Sankyo and are covered by U.S. Patent No. 5,616,599. It discloses olmesartan medoxomil and other related imidazoles. It also describes a process for the preparation of imidazole derivatives useful for the synthesis of olmesartan.
Olmesartan medoxomil is practically insoluble in water. This leads to a low rate of dissolution of olmesartan medoxomil in aqueous media (including gastrointestinal fluids), which results in inadequate bioavailability after oral ingestion.
Two most common approaches employed in the prior art to increase the dissolution rate of a poorly soluble drug are either a reduction of the particle size of the drug or the addition of a surfactant. Reduction of particle size leads to increased surface area and addition of surfactant improves the surface properties of the drug particles, thereby improving the dissolution characteristics of a poorly soluble drug.
For most of the drugs neither of the approaches used alone improve dissolution characteristics. The reduction of the particle size of hydrophobic drugs also lead to increased surface charges (static charges) resulting in the agglomeration of the particles, especially in an aqueous media because of thermodynamic repulsion. This results in significant decrease in the effective or exposed surface area available for dissolution. This tendency of micronized particles to agglomerate is generally reduced by the addition of a surfactant.
WO 2007/047838 relates to a process of preparing olmesartan medoxomil having decreased impurities and a particle size distribution such that the do.9 is less than 250 μπι.
WO 2008/117707 relates to ground crystals of olmesartan medoxomil having particle size distribution such that the d0.9 is less than 75 μπι, preferably less than 66 μπι and most preferably less than 57 μπι.
The present inventors have found that further reduction of the particle size of olmesartan medoxomil (i.e., less than 50 μπι), even without addition of a surfactant leads to remarkably improved solubility characteristics and as a result, a pharmaceutical composition having an improved dissolution profile is obtained.
Summary of the Invention
In one general aspect, the present invention provides for a pharmaceutical composition that includes micronized particles of olmesartan medoxomil having a d0.9 less than 50 μπι and one or more pharmaceutically acceptable excipients.
Embodiments of this aspect may include one or more of the following features. For example, the micronized particles of olmesartan medoxomil have a d0.9 between 2 μπι to 25 μπι. The micronized particles of olmesartan medoxomil may have a d0.9 between 4 μπι to 10 μπι.
The micronized particles of olmesartan medoxomil are present in an amount of about 2% to about 80% by weight of the composition. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients selected from a group comprising diluents, binders, disintegrants, lubricants, glidants, surfactants, coloring agents or flavoring agents.
The pharmaceutical composition is in the form of a tablet, dispersible tablet, capsule, granule, pellet, bead, powder, suspension, elixir or syrup. The composition is prepared by directly encapsulating or directly compressing olmesartan with one or more excipients. For example, the composition may be prepared by wet granulating olmesartan with one or more excipients prior to encapsulation or compression. The composition may also be prepared by dry granulating olmesartan with one or more excipients prior to encapsulation or compression.
The pharmaceutical composition is used for the treatment or prophylaxis of hypertension or of a cardiovascular disease by administering to a person in need thereof and may be administered in combination with an additional antihypertensive agent.
Suitable additional antihypertensive agents include one or more of thiazide diuretics, β-blockers, calcium channel blockers, rennin inhibitors or ACE inhibitors. For example, the composition may include micronized olmesartan medoxomil particles having a d0.9 less than 50 μπι and hydrochlorothiazide.
In another general aspect, the present invention provides for a pharmaceutical composition that includes micronized olmesartan medoxomil particles and amlodipine, wherein the micronized olmesartan particles have a do.9 less than 50 μπι.
In another general aspect, the present invention provides for olmesartan medoxomil particles having a d0.9 less than 50 μπι. Embodiments of this aspect may include one or more of the following features. For example, the olmesartan medoxomil particles may have a do.9 between 2 μπι to 25 μπι or a do.9 between 4 μπι to 10 μπι.
Detailed Description of the Invention
The present invention provides a novel pharmaceutical composition comprising micronized olmesartan medoxomil and processes thereof.
The term "olmesartan medoxomil", as used herein, includes crystalline or amorphous olmesartan medoxomil. In the compositions of the present invention, olmesartan medoxomil may be utilized in an amount ranging from 2% to 80% (w/w) based on the total weight of the pharmaceutical composition.
As used herein, the phrase "micronized olmesartan medoxomil" means particles of olmesartan medoxomil having d0.9 less than 50 μπι, particularly between 1 μπι to 50 μπι, more particularly between 2 μπι to 25 μπι. Most particularly, it relates to olmesartan medoxomil particles having do.9 between 4 μπι to 10 μπι.
The term "do.9", as used herein, with reference to the size of micronized olmesartan medoxomil particles, indicate that about 90% of particles measured have a size less than the defined d0.9 value, and that about 10% of particles measured have a size greater than the defined d0.9 value.
The phrase "therapeutically effective amount", as used herein, means a dosage that is sufficient to provide the specific pharmacological response for which the olmesartan medoxomil is being administered. The "therapeutically effective amount" will vary depending on the severity of the disease, age, weight, physical condition and the responsiveness of the subject.
The particle size distribution of olmesartan medoxomil particles of the present invention may be determined using an optical microscopic method, sedimentation techniques, for example, pipette analysis using an Andreas sen pipette, sedimentation scales, photo sedimentometers or sedimentation in a centrifugal force field, pulse methods, for example, using a Coulter counter, or sorting by means of gravitational or centrifugal force, sieve analysis, laser diffraction or ultrasound attenuation spectroscopy. The particle size distribution of olmesartan medoxomil particles of the present invention is particularly determined through laser diffraction using a Malvern® Mastersizer laser diffraction instrument.
The pharmaceutical composition that includes micronized olmesartan medoxomil may further comprise one or more pharmaceutically acceptable excipients selected from a group comprising diluents, binders, disintegrants, lubricants, coloring agents, flavoring agents or any other excipients known in the art.
Suitable examples of diluents include corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch, pregelatinized starch or mixtures thereof.
Suitable examples of binders include polyvinylpyrrolidone, starch mucilage, pregelatinized starch, sodium alginate, alginic acid, acacia mucilage, tragacanth, hydroxypropylmethyl cellulose, carboxymethylcellulose sodium, carboxymethylcellulose calcium, microcrystalline cellulose, ethyl cellulose, polyethylene glycol, hydroxyethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polymethacrylates, carboxyvinyl polymers, carbopols, and combinations thereof. Suitable examples of disintegrants include cross-linked polyvinylpyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose (crosscarmellose sodium), calcium carboxymethyl cellulose, alginic acid and alginates, pregelatinised starch, starch and starch derivatives, low-substituted hydroxypropyl cellulose and combinations thereof.
Examples of lubricants and glidants include colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, white beeswax or mixtures thereof.
Coloring agents and flavoring agents may be selected from any FDA approved colors and flavors for oral use.
The pharmaceutical compositions of the present invention may optionally contain surfactants.
Surfactants/wetting agents include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in pharmaceutical compositions. These include polyethoxylated fatty acid esters, polyethylene glycol fatty acid esters, alcohol-oil transesterification products, polyglycerized fatty acids, polyethylene glycol sorbitan fatty acid esters, sugar esters, polyoxyethylene-polyoxypropylene block copolymers, ionic surfactants, derivatives of fat soluble vitamins, and mixtures thereof. Suitable examples include sodium lauryl sulphate, sodium dodecyl sulphate, polyoxyethylene castor oil derivatives, for example, tweens, polyoxyethylene-polyoxypropylene block copolymers, for example, poloxamer, or mixtures thereof.
The present invention further provides pharmaceutical composition that include micronized olmesartan medoxomil, wherein the composition may be in the form of tablets, dispersible tablets, capsules, granules, beads, pellets, powder, suspension, emulsion, syrups or elixirs. Particularly, the compositions of the present invention are formulated into tablets, capsules or dispersible tablets. Further, the tablets may be film-coated.
The tablets may be coated using a sugar-based agent, an agent for water-soluble film-coating base, enteric film-coating agent or a modified release film-coating agent. The coating agent may also contain a plasticizer.
The oral pharmaceutical compositions of the present invention may be prepared by using the conventional techniques, for example, either by direct compression, or first slugging some of the ingredients, milling the slugs, blending with the remaining ingredients and then compressing as appropriate. These compositions may also be prepared using wet granulation techniques.
The pharmaceutical composition according to the present invention comprising micronized olmesartan medoxomil may be administered for the treatment or prophylaxis of hypertension or of a cardiocascular disease.
Further, pharmaceutical compositions, described herein, can also be administered in combination with other antihypertensive agents selected from thiazide diuretics, β- blockers, calcium channel blockers, rennin inhibitors or ACE inhibitors.
The following examples represent various embodiments according to the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
Examples: 1, 2, 3 & 4
Tablets containing olmesartan medoxomil having a do.9 of 116 μπι, 67 μπι, 22 μηι and 6 μηι respectively.
Figure imgf000007_0001
Process:
Olmesartan medoxomil and microcrystalline cellulose were sieved and blended together. (ii) Lactose monohydrate and L-hydroxypropylcellulose were sieved and mixed with the blend of step (i).
(iii) Hydroxypropylcellulose was dissolved in purified water.
(iv) Blend of step (ii) was granulated using the binder solution of step (iii).
(v) Granules of step (iv) were dried in a fluidized bed dryer.
(vi) Dried granules of step (v) were sieved.
(vii) Magnesium stearate was mixed with granules of step (vi).
(viii) Finally the blend of step (vii) was compressed into tablets.
(ix) The coating material was dispersed in purified water to prepare coating solution.
(x) The compressed tablets were then coated using coating solution of step (ix).
Comparison of In- Vitro Dissolution Profile
The tablets of olmesartan medoxomil prepared as per the compositions of Examples 1, 2, 3 and 4 were subjected to dissolution studies in 1000 ml of phosphate buffer (pH 6.8) at 37°C using USP apparatus II with paddle speed at 50 rpm. Table 1 provides comparative dissolution profile.
Table 1:
Figure imgf000008_0001
Comparative dissolution profile of the Examples 1, 2, 3 and 4 indicate that as I particle size of olmesartan medoxomil decreases the dissolution percentage increases.

Claims

We Claim:
1. A pharmaceutical composition comprising micronized particles of olmesartan medoxomil having a do.9 less than 50 μπι and one or more pharmaceutically acceptable excipients.
2. The pharmaceutical composition of claim 1, wherein the micronized particles of olmesartan medoxomil have a d0.9 between 2 μπι to 25 μπι.
3. The pharmaceutical composition of claim 1, wherein the micronized particles of olmesartan medoxomil have a do.9 between 4 μπι to 10 μπι.
4. The pharmaceutical composition of claim 1, wherein the micronized particles of olmesartan medoxomil are present in an amount of about 2% to about 80% by weight of the composition.
5. The pharmaceutical composition of claim 1, further comprising one or more pharmaceutically acceptable excipients are selected from a group comprising diluents, binders, disintegrants, lubricants, glidants, surfactants, coloring agents or flavoring agents.
6. The pharmaceutical composition of claim 1, wherein the composition is in the form of a tablet, dispersible tablet, capsule, granule, pellet, bead, powder, suspension, elixir or syrup.
7. The pharmaceutical composition of claim 6, wherein the composition is in the form of a tablet, capsule or dispersible tablet.
8. The pharmaceutical composition of claim 7, wherein the composition is prepared by directly encapsulating or directly compressing olmesartan with one or more excipients.
9. The pharmaceutical composition of claim 7, wherein the composition is prepared by wet granulating olmesartan with one or more excipients prior to encapsulation or compression.
10. The pharmaceutical composition of claim 7, wherein the composition is prepared by dry granulating olmesartan with one or more excipients prior to encapsulation or compression.
11. The pharmaceutical composition of claim 1, wherein the composition is used for the treatment or prophylaxis of hypertension or of a cardiovascular disease by administering to a person in need thereof.
12. The pharmaceutical composition of claim 1, wherein the composition is administered in combination with an additional antihypertensive agent.
13. The pharmaceutical composition of claim 12, wherein the additional antihypertensive agent comprises one or more of thiazide diuretics, β-blockers, calcium channel blockers, rennin inhibitors or ACE inhibitors.
14. The pharmaceutical composition of claim 13, wherein the composition comprises micronized olmesartan medoxomil particles having a d0.9 less than 50 μπι and hydrochlorothiazide.
15. A pharmaceutical composition comprising micronized olmesartan medoxomil particles and amlodipine, wherein the micronized olmesartan particles have a d0.9 less than 50 μπι.
16. Olmesartan medoxomil particles having a do.9 less than 50 μπι.
17. Olmesartan medoxomil particles according to claim 16, wherein the particles have a d0.9 between 2 μπι to 25 μπι.
18. Olmesartan medoxomil particles according to claim 16, wherein the particles have a do.9 between 4 μπι to 10 μπι.
PCT/IB2010/054641 2009-10-13 2010-10-13 Micronized olmesartan medoxomil compositions WO2011045760A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2119/DEL/2009 2009-10-13
IN2119DE2009 2009-10-13

Publications (2)

Publication Number Publication Date
WO2011045760A2 true WO2011045760A2 (en) 2011-04-21
WO2011045760A3 WO2011045760A3 (en) 2012-01-05

Family

ID=43413907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/054641 WO2011045760A2 (en) 2009-10-13 2010-10-13 Micronized olmesartan medoxomil compositions

Country Status (1)

Country Link
WO (1) WO2011045760A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
CN103263395A (en) * 2013-06-10 2013-08-28 南京正宽医药科技有限公司 Telmisartan tablet preparation and preparation method thereof
WO2014002011A1 (en) * 2012-06-26 2014-01-03 Micro Labs Limited Micronized particles of olmesartan medoxomil and pharmaceutical composition thereof
WO2014030082A1 (en) 2012-08-22 2014-02-27 Lupin Limited Novel method to obtain olmesartan medoxomil with reduced particle size
JP2016044170A (en) * 2014-08-27 2016-04-04 日本ケミファ株式会社 Olmesartan prodrug formulation
JP2017008018A (en) * 2015-06-19 2017-01-12 日本ジェネリック株式会社 Olmesartan medoxomil tablet in which elution properties are improved

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
WO2007047838A2 (en) 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Process for preparing olmesartan medoxomil
WO2008117707A1 (en) 2007-03-23 2008-10-02 Daiichi Sankyo Company, Limited Ground crystal of olmesartan medoxomil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281800A1 (en) * 2005-04-12 2006-12-14 Glenmark Pharmaceuticals Limited Polymorphic form of olmesartan and process for its preparation
EP1891952B1 (en) * 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmaceutical composition of olmesartan medoxomil
JP5554699B2 (en) * 2008-03-13 2014-07-23 第一三共株式会社 Improving dissolution properties of formulations containing olmesartan medoxomil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
WO2007047838A2 (en) 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Process for preparing olmesartan medoxomil
WO2008117707A1 (en) 2007-03-23 2008-10-02 Daiichi Sankyo Company, Limited Ground crystal of olmesartan medoxomil

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
WO2014002011A1 (en) * 2012-06-26 2014-01-03 Micro Labs Limited Micronized particles of olmesartan medoxomil and pharmaceutical composition thereof
WO2014030082A1 (en) 2012-08-22 2014-02-27 Lupin Limited Novel method to obtain olmesartan medoxomil with reduced particle size
CN103263395A (en) * 2013-06-10 2013-08-28 南京正宽医药科技有限公司 Telmisartan tablet preparation and preparation method thereof
JP2016044170A (en) * 2014-08-27 2016-04-04 日本ケミファ株式会社 Olmesartan prodrug formulation
JP2017008018A (en) * 2015-06-19 2017-01-12 日本ジェネリック株式会社 Olmesartan medoxomil tablet in which elution properties are improved

Also Published As

Publication number Publication date
WO2011045760A3 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
EP2623100B1 (en) Preparation for improving solubility of poorly soluble drug
EP2229938B9 (en) Ezetimibe compositions
US20110070303A1 (en) Novel dosage formulation
WO2011045760A2 (en) Micronized olmesartan medoxomil compositions
CN108125921B (en) Posaconazole solid dispersion composition capable of inhibiting crystallization and preparation method thereof
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
EP2242483B1 (en) Raloxifene composition
US20100062070A1 (en) Pulverzed crystals of olmesartan medoxomil
EP2916871B1 (en) Co-micronisation product comprising ulipristal acetate
CN102143738A (en) Pharmaceutical solid preparation
JP2012530126A (en) Nanoparticulate olmesartan medoxomil composition, method for its preparation, and pharmaceutical composition containing them
WO2012172461A1 (en) Pharmaceutical compositions of febuxostat
JP2023184662A (en) istradefylline preparation
TWI402083B (en) Solid dosage form and stabilization method thereof
TWI414310B (en) Elution-improved pharmaceutical preparation
WO2007026261A2 (en) Formulations containing losartan and/or its salts
WO2019180735A1 (en) Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US20140093563A1 (en) Febuxostat compositions
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
CN114533735A (en) Lurasidone hydrochloride pharmaceutical composition and preparation method thereof
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2010146551A2 (en) Orally disintegrating compositions comprising antihypertensive agents
US20200078309A1 (en) Stable tablet compositions of Sacubitril: Valsartan
EP2520300A1 (en) Pharmaceutical composition for oral administration
WO2014002011A9 (en) Micronized particles of olmesartan medoxomil and pharmaceutical composition thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782690

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782690

Country of ref document: EP

Kind code of ref document: A2